Mark Tardie

Mark Tardie is a seasoned biophysical chemist and regulatory strategist with extensive experience in the pharmaceutical industry. Mark began a career at Henry Souther Laboratories as an Analytical Chemist and later served as a Senior Associate Scientist at Regeneron Pharmaceuticals, focusing on the formulation of biological assets. Mark returned to Pfizer in various roles, including Scientist and Associate Director of Worldwide Regulatory Strategy in Oncology, where responsibilities included managing global regulatory strategies for early development oncology assets. Currently, Mark holds the position of Director of Worldwide Regulatory Strategy, Oncology at Pfizer, overseeing global regulatory strategy for multiple myeloma and metastatic colorectal cancer studies. Mark's educational background includes a BS in Biology/Chemistry from Central Connecticut State University, an MS in Biochemistry from the University of Connecticut, and a Certificate in Pharmaceutical Regulatory Affairs from Temple University.